Blood test aims to catch Lymphoma's return sooner after CAR-T treatment
NCT ID NCT05675982
Summary
This study is testing if a blood test can quickly detect tiny amounts of leftover cancer after patients receive CAR-T cell therapy for a type of lymphoma that has come back or not responded to other treatments. The goal is to see if getting these test results within three weeks can help doctors spot a possible relapse earlier. If successful, this could allow for earlier additional treatment to try to improve patient outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Henri Becquerel
Rouen, France
Conditions
Explore the condition pages connected to this study.